ratjadone and HIV-Infections

ratjadone has been researched along with HIV-Infections* in 1 studies

Other Studies

1 other study(ies) available for ratjadone and HIV-Infections

ArticleYear
The myxobacterial metabolite ratjadone A inhibits HIV infection by blocking the Rev/CRM1-mediated nuclear export pathway.
    Microbial cell factories, 2014, Jan-29, Volume: 13

    The nuclear export of unspliced and partially spliced HIV-1 mRNA is mediated by the recognition of a leucine-rich nuclear export signal (NES) in the HIV Rev protein by the host protein CRM1/Exportin1. This makes the CRM1-Rev complex an attractive target for the development of new antiviral drugs. Here we tested the anti-HIV efficacy of ratjadone A, a CRM1 inhibitor derived from myxobacteria.. Ratjadone A inhibits HIV infection in vitro in a dose-dependent manner with EC₅₀ values at the nanomolar range. The inhibitory effect of ratjadone A occurs around 12 hours post-infection and is specific for the Rev/CRM1-mediated nuclear export pathway. By using a drug affinity responsive target stability (DARTS) assay we could demonstrate that ratjadone A interferes with the formation of the CRM1-Rev-NES complex by binding to CRM1 but not to Rev.. Ratjadone A exhibits strong anti-HIV activity but low selectivity due to toxic effects. Although this limits its potential use as a therapeutic drug, further studies with derivatives of ratjadones might help to overcome these difficulties in the future.

    Topics: Active Transport, Cell Nucleus; Antiviral Agents; Cell Line; Exportin 1 Protein; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Karyopherins; Myxococcales; Protein Binding; Pyrones; Receptors, Cytoplasmic and Nuclear; rev Gene Products, Human Immunodeficiency Virus; RNA, Messenger

2014